leisure time -WSS

leisure time

author：comprehensive 2025-09-01 15:14:57 - browse：81

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Sweden knocks USA out of World Cup in penalty kicks

WSS

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Can sheer will power keep patients alive in their dying hours?

Pennsylvania man bitten on the head by bear during attack in his garage

Paxlovid rebound happens. Why and to whom are still a mystery

knowledge

leisure time

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Kansas bar where gunfire wounded 9 last month closes permanently

Hollywood unions extend contract negotiations for actors

Paxlovid rebound happens. Why and to whom are still a mystery

Dobbs anniversary: the lost opportunity of abortion as health care

Virtual care provider acquires bankrupt Pear's prescription apps

Trump demands the U.S. pay no more for drugs than other countries … again

SEC charges former device maker CEO with $41 million fraud

How to save PrEP access — and even expand it

Paxlovid rebound happens. Why and to whom are still a mystery

focus

CRISPR gene editing developments we’re watching in 2024

Feed a cold, starve a fever? Here’s what science says

Sage considers ways to reduce costs following FDA rejection

Hospitals owned by private equity see complications spike 25%

Slovenia has suffered its worst

Slovenia has suffered its worst

hotspot

explore

explore

Wikipedia